DDInter1814 DDInter927
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Tioguanine {u} (Compound) treats {v} (Disease) hematologic cancer
Tioguanine {u} (Compound) binds {v} (Gene) IMPDH2
Tioguanine {u} (Compound) causes {v} (Side Effect) Portal hypertension
Tioguanine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Tioguanine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Tioguanine (Compound) resembles Adenine (Compound)
Tioguanine (Compound) treats hematologic cancer (Disease)
Tioguanine (Compound) binds IMPDH2 (Gene)
Tioguanine (Compound) causes Portal hypertension (Side Effect)
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab
Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Tioguanine may lead to a major life threatening interaction when taken with Cladribine
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine